Literature DB >> 10861472

p185(neu) protein is required for tumor and anchorage-independent growth, not for cell proliferation of transgenic mammary carcinoma.

P Nanni1, S M Pupa, G Nicoletti, C De Giovanni, L Landuzzi, I Rossi, A Astolfi, C Ricci, R De Vecchi, A M Invernizzi, E Di Carlo, P Musiani, G Forni, S Menard, P L Lollini.   

Abstract

Transgenic FVB-NeuN mice (N202) bearing the rat neu protooncogene driven by the mouse mammary tumor virus promoter/enhancer develop focal mammary carcinomas overexpressing the neu-encoded p185(neu) protein. In vitro expression of p185(neu) among mammary carcinoma cultures was heterogeneous, and we could establish some cell lines and clones displaying a complete loss of p185(neu) expression, along with others with very high p185(neu) protein level. Upon in vivo injection, p185(neu)-positive cells gave rise to fast-growing tumors with a short latency, while p185(neu)-negative cells required a very long latency time, and the resulting tumors were invariably p185(neu)-positive. The lower growth ability of p185(neu)-negative cells in vivo was also confirmed in athymic nude mice. In vitro, analysis of anchorage-independent growth in soft agar revealed colony formation from p185(neu)-positive but not p185(neu)-negative cells. The direct involvement of p185(neu) in clonogenicity was demonstrated by the inhibition of p185(neu)-positive colony growth in soft agar in the presence of an anti-p185(neu) monoclonal antibody. By contrast, a higher level of anchorage-dependent clonogenic growth and proliferation was observed in p185(neu)-negative cells as compared to p185(neu)-positive cells, thus explaining the relative ease with which p185(neu)-negative cell lines and clones were established in vitro. Together, the results indicate that p185(neu) expression can lead to tumor formation and metastasis through the modification of intrinsic properties of cells related to anchorage-independent growth ability rather than to proliferation or host-dependent mechanisms. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10861472

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  22 in total

1.  Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma.

Authors:  Annalisa Astolfi; Lorena Landuzzi; Giordano Nicoletti; Carla De Giovanni; Stefania Croci; Arianna Palladini; Silvano Ferrini; Manuela Iezzi; Piero Musiani; Federica Cavallo; Guido Forni; Patrizia Nanni; Pier-Luigi Lollini
Journal:  Am J Pathol       Date:  2005-04       Impact factor: 4.307

2.  Dysregulation of HER2/HER3 signaling axis in Epstein-Barr virus-infected breast carcinoma cells.

Authors:  Jiun-Han Lin; Ching-Hwa Tsai; Jan-Show Chu; Jeou-Yuan Chen; Kenzo Takada; Jin-Yuh Shew
Journal:  J Virol       Date:  2007-03-21       Impact factor: 5.103

3.  Oral vaccination with adeno-associated virus vectors expressing the Neu oncogene inhibits the growth of murine breast cancer.

Authors:  Jason C Steel; Giovanni Di Pasquale; Charmaine A Ramlogan; Vyomesh Patel; John A Chiorini; John C Morris
Journal:  Mol Ther       Date:  2013-01-08       Impact factor: 11.454

4.  Interleukin-15 and its receptor augment dendritic cell vaccination against the neu oncogene through the induction of antibodies partially independent of CD4 help.

Authors:  Jason C Steel; Charmaine A Ramlogan; Ping Yu; Yoshio Sakai; Guido Forni; Thomas A Waldmann; John C Morris
Journal:  Cancer Res       Date:  2010-01-19       Impact factor: 12.701

5.  Interference with activator protein-2 transcription factors leads to induction of apoptosis and an increase in chemo- and radiation-sensitivity in breast cancer cells.

Authors:  Verena Thewes; Francesca Orso; Richard Jäger; Dawid Eckert; Sabine Schäfer; Gregor Kirfel; Stephan Garbe; Daniela Taverna; Hubert Schorle
Journal:  BMC Cancer       Date:  2010-05-11       Impact factor: 4.430

6.  Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition.

Authors:  María M Caffarel; Clara Andradas; Emilia Mira; Eduardo Pérez-Gómez; Camilla Cerutti; Gema Moreno-Bueno; Juana M Flores; Isabel García-Real; José Palacios; Santos Mañes; Manuel Guzmán; Cristina Sánchez
Journal:  Mol Cancer       Date:  2010-07-22       Impact factor: 27.401

Review 7.  Ste20-like kinase SLK, at the crossroads: a matter of life and death.

Authors:  Khalid N Al-Zahrani; Kyla D Baron; Luc A Sabourin
Journal:  Cell Adh Migr       Date:  2012-11-15       Impact factor: 3.405

8.  Tumor regression following DNA vaccination and regulatory T cell depletion in neu transgenic mice leads to an increased risk for autoimmunity.

Authors:  Jennifer B Jacob; Yi-chi M Kong; Ilke Nalbantoglu; Daniel P Snower; Wei-Zen Wei
Journal:  J Immunol       Date:  2009-05-01       Impact factor: 5.422

9.  Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas.

Authors:  Claudia Curcio; Emma Di Carlo; Raphael Clynes; Mark J Smyth; Katia Boggio; Elena Quaglino; Michela Spadaro; Mario P Colombo; Augusto Amici; Pier-Luigi Lollini; Piero Musiani; Guido Forni
Journal:  J Clin Invest       Date:  2003-04       Impact factor: 14.808

10.  Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma.

Authors:  Cecilia Melani; Sabina Sangaletti; Francesca M Barazzetta; Zena Werb; Mario P Colombo
Journal:  Cancer Res       Date:  2007-12-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.